옵션 체인은 다양한 행사가격과 만기일에 대한 Quantum의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Quantum에 대한 시장 심리를 평가합니다..

Quantum (NASDAQ:QMCO) 주식, 옵션 체인

Quantum

Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data. The company provides solutions for the entire data lifecycle. The company specialize in solutions for video, images, audio, and other large files. The company's portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The company's Primary Storage Software and Systems include Myriad All-Flash Software-Defined Storage, StorNext Hybrid Flash/Disk File Storage Software, and Unified Surveillance Platform Software. Secondary Storage Software and Systems include ActiveScale Object Storage Software and DXi Backup Appliances. The firm derives the majority of its revenue from United States.

Equities

News

Markets

AMZN

QMCO

TSLA

제롬 파월 연준 의장의 발언 이후 미국 주식 시장은 격동의 하루를 보냈다. 파월 의장이 향후 금리 인하에 대해 신중한 접근을 하겠다고 발표하면서 시장 변동성을 높였다. 마이크론 테크놀로지, 퀀텀 코퍼레이션, 메타, 아마존 및 테슬라

수요일 주목받은 주식: 마이크론 테크놀로지, 퀀텀 코퍼레이션, 메타, 아마존 및 테슬라

NVDA

RGTI

리제티 컴퓨팅(NASDAQ:RGTI)의 주식이 금요일 52주 최고가를 경신하며 $4.39에 도달했다. 이는 지난 1년 동안 321.15%의 놀라운 상승률을 나타내며, 투자자들이 회사의 미래에 대해 긍정적인 신뢰를 가지고 있음을 시사한다.

리제티 컴퓨팅, 투자자 신뢰가 급증하여 52주 최고가 경신

Earnings

Pre-Market Outlook

Trading Ideas

NFBK

RRGB

월요일 아침(현지 시간) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 일부 주식은 다음과 같다: 월스트리트는 레나 코퍼레이션(NYSE:LEN)이 시장 마감 후 분기별 이익은 주당 3.24달러, 매출은 85억 2천만 달러로 보고할 것으로 예상한다. 벤징가 프로의 데이터에 따르면 레나의 주가는 금요일에 0.04% 상승한 155.10달러에 마감했다. 

레나, 레이지보이 그리고 월요일 주목해야 할 주식 3종목

Quantum Corp

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy and maintains $128 price target.

Price Target

Analyst Ratings

BMEA

D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $128 Price Target

Stephens &amp; Co. analyst Jim Salera reiterates Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Equal-Weight and maintains $164 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Darden Restaurants, Maintains $164 Price Target

Northcoast Research analyst Aaron Reed initiates coverage on Tennant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNC#NYSE">TNC</a>) with a Buy rating and announces Price Target of $125.

Initiation

Northcoast Research Initiates Coverage On Tennant with Buy Rating, Announces Price Target of $125

Rodman &amp; Renshaw analyst Tony Butler initiates coverage on TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) with a Buy rating and announces Price Target of $11.

HURA

Rodman & Renshaw Initiates Coverage On TuHURA Biosciences with Buy Rating, Announces Price Target of $11

WIIM

PHIO

Phio Pharmaceuticals shares are trading higher after the company announced that the Safety Monitoring Committee recommended dose escalation in its Phase 1B trial evaluating PH-762 for various advanced cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

Baird analyst Tristan Gerra maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Outperform and lowers the price target from $150 to $130.

Baird Maintains Outperform on Micron Technology, Lowers Price Target to $130

Keybanc analyst Eric Heath downgrades C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) from Sector Weight to Underweight and announces $29 price target.

Downgrades

Keybanc Downgrades C3.ai to Underweight, Announces $29 Price Target

Vladimir Putin, the President of Russia, has <a href="https://www.benzinga.com/news/global/24/11/41865062/putin-congratulates-trump-on-2024-election-victory-russian-leader-said-president-elect-manly-for-how-he-handled-assassination-attempt">shown his readiness to initiate talks</a> with the incoming U.S. President Donald Trump. 
What Happened: In his annual televised press conference held in Moscow, Putin stated his readiness to engage in dialogue with Trump,  <a href="https://www.bloomberg.com/news/articles/2024-12-19/putin-says-he-s-ready-to-meet-trump-hasn-t-seen-syria-s-assad">Bloomberg</a> on Thursday.
&#8220;I&#8217;m ready for it, of course, at any time. And I&#8217;ll be ready to meet if he wants,&#8221; he said. Trump, who is due to begin his second term as US president on Jan.20, has expressed his intent to resolve the ongoing war between Russia and Ukraine, which has been ongoing for nearly three years.
Trump Campaign did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/24/12/42522048/jim-cramer-warns-nvidias-vicious-and-fast-reversal-is-coming-amid-174-surge-this-year-and-china-antitrust-probe?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Warns Nvidia&#8217;s &#8216;Vicious&#8217; And &#8216;Fast&#8217; Reversal Is Coming Amid 174% Surge This Year And China Ant</a>
Trump has also hinted at his expectation for Putin to be open to a deal. However, the details of how he intends to bring both parties to the negotiation table and the terms of the potential agreement remain undisclosed.
Why It Matters: Putin also disclosed that he has not had any interaction with the deposed Syrian President Bashar al-Assad, who sought refuge in Moscow earlier this month. &#8220;I haven&#8217;t seen President Assad since his arrival in Moscow,&#8221; Putin stated. He also mentioned his plans to meet with Assad to discuss various matters, including the case of Austin Tice, the American journalist who has been missing. Earlier, Trump <a href="https://www.benzinga.com/news/global/24/12/42380085/trump-on-assads-fall-putin-was-not-interested-in-protecting-him-any-longer">commented on Putin&#8217;s lack of interest</a> in protecting Assad following the dictator&#8217;s fall.
Meanwhile, a book by journalist Bob Woodward in October<a href="https://www.benzinga.com/general/politics/24/10/41235596/trump-secretly-stayed-in-contact-with-putin-after-leaving-office-upcoming-bob-woodward-book-alle"> reportedly alleged that Trump and Russian President </a>Putin have spoken as many as seven times since 2021.
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42516580/ionq-quantum-computing-and-rigetti-computing-shares-are-soaring-monday-whats-going-on?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">IonQ, Quantum Computing And Rigetti Computing Shares Are Soaring Monday: What&#8217;s Going On?</a>
Image via Kremlin

Politics

General

Russian President Says He's Willing To Meet Trump 'At Any Time' For Dialogue

Baird analyst Mark Altschwager maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and raises the price target from $65 to $72.

BIRK

Baird Maintains Outperform on Birkenstock Holding, Raises Price Target to $72

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Biotech

Health Care

Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1B Trial To Evaluate The Safety And Tolerability Of PH-762 For Stages 1, 2, And 4 Cutaneous Squamous Cell Carcinoma, Stage 4 Melanoma, And Stage 4 Merkel Cell Carcinoma

"We are encouraged by the early evidence of responses in patients with cold tumors, including MSS colorectal cancer, reported for the combination of vilastobart and atezolizumab in Phase 1C dose escalation earlier this year, and we look forward to sharing initial Phase 2 data for the combination in MSS CRC at ASCO GI in January," said Katarina Luptakova, M.D., chief medical officer of Xilio.
"In addition, the preliminary Phase 1 data we reported today for XTX301, our tumor-activated IL-12, highlight its promising clinical profile, including no dose-limiting toxicities reported to date and consistent interferon gamma signaling observed throughout treatment cycles."

Xilio To Present Initial Data From Its Ongoing Phase 2 Trial For Vilastobart At ASCO GI; Reports Preliminary Phase 1 Data For XTX301 Showing Improved Tolerability Profile Over Historical Data For rhIL-12

Deutsche Bank analyst David Begleiter maintains PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) with a Buy and lowers the price target from $150 to $145.

Deutsche Bank Maintains Buy on PPG Indus, Lowers Price Target to $145

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Paychex Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>)</h3>
<ul>
<li>On Nov. 19, JP Morgan analyst Tien-Tsin Huang maintained Paychex with an Underweight rating and raised the price target from $133 to $139. The company's stock fell around 4% over the past five days and has a <a href="https://www.benzinga.com/quote/PAYX">52-week low of $114.72</a>.</li>
<li>RSI Value: 29.58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>PAYX Price Action: Shares of Paychex fell 3.2% to close at $135.86 on Wednesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1">latest PAYX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164.png" alt="" class="wp-image-699579" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164-768x719.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Sunrun Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Dec. 17, Goldman Sachs analyst Brian Lee maintained Sunrun with a Buy and lowered the price target from $19 to $17. The company's stock fell around 12% over the past five days and <a href="https://www.benzinga.com/quote/RUN">has a 52-week low</a> of $9.13.</li>
<li>RSI Value: 28.40</li>
<li>RUN Price Action: Shares of Sunrun fell 9.1% to close at $9.15 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"> trend in RUN stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165.png" alt="" class="wp-image-699581" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165-768x706.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">A O Smith Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>)</h3>
<ul>
<li>On Dec. 11, Stifel analyst Nathan Jones maintained A.O. Smith with a Buy and lowered the price target from $91 to $90. The company's stock fell around 5% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/AOS">low of $68.89.</a></li>
<li>RSI Value: 25.09</li>
<li>AOS Price Action: Shares of A O Smith fell 2.7% to close at $68.91 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1">breakout in AOS shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="927" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166.png" alt="" class="wp-image-699582" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166-768x693.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42553288/top-3-tech-and-telecom-stocks-that-may-crash-this-month">Top 3 Tech And Telecom Stocks That May Crash This Month</a></li>
</ul>

Long Ideas

PAYX

Top 3 Industrials Stocks Which Could Rescue Your Portfolio For December

Deutsche Bank analyst David Begleiter maintains Axalta Coating Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) with a Buy and lowers the price target from $44 to $42.

AXTA

Deutsche Bank Maintains Buy on Axalta Coating Sys, Lowers Price Target to $42

Wells Fargo analyst Derek Archila downgrades Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) from Overweight to Equal-Weight and lowers the price target from $12 to $6.

CABA

Wells Fargo Downgrades Cabaletta Bio to Equal-Weight, Lowers Price Target to $6

Keybanc analyst Eric Heath upgrades Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) from Sector Weight to Overweight and announces $115 price target.

Upgrades

FTNT

Keybanc Upgrades Fortinet to Overweight, Announces $115 Price Target

Deutsche Bank analyst Steve Powers maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Hold and lowers the price target from $72 to $68.

Deutsche Bank Maintains Hold on General Mills, Lowers Price Target to $68

Deutsche Bank analyst Krisztina Katai maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Buy and raises the price target from $65 to $66.

Deutsche Bank Maintains Buy on Birkenstock Holding, Raises Price Target to $66

Wells Fargo analyst Derek Archila upgrades C4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCC#NASDAQ">CCCC</a>) from Equal-Weight to Overweight and raises the price target from $8 to $12.

CCCC

Wells Fargo Upgrades C4 Therapeutics to Overweight, Raises Price Target to $12

10:11 EST Quantum (QMCO) Corp trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

Quantum Corp trading resumes

10:06 EST Quantum (QMCO) Corp trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving...

Quantum Corp trading halted, volatility trading pause

Analysts have been eager to weigh in on the Technology sector with new ratings on Quantum (QMCO – Research Report), ACM Research (ACMR – Research R...

Analysts' Opinions Are Mixed on These Technology Stocks: Quantum (QMCO), ACM Research (ACMR) and Chegg (CHGG)

Since the "quantum" news from Google last week, smaller companies focused on quantum computing have skyrocketed.

Quantum Stocks Leap

09:56 EST Quantum (QMCO) Corp trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

09:51 EST Quantum (QMCO) Corp trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving...

Quantum's Future Feels Cloudy As Hype Outpaces Results

Quantum (QMCO) Corporation announced development of a new highly parallel file system client for the Quantum Myriad all-flash file system, designed...

Quantum announces support for 'NVIDIA GPUDirect Storage' capability

11:59 EST Quantum (QMCO) Corp trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

11:54 EST Quantum (QMCO) Corp trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving...

Comments

Quantum

Quantum (QMCO) 옵션

Quantum (NASDAQ:QMCO) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌